Research News

The SIREN study is a study that monitors the impact of detectable anti SARS-COV2 antibody on the incidence of COVID19 in healthcare workers. This national project is an Urgent Public Health study aimed at onsite hospital employees who are ideally patient facing, but also who may have contact with patients as they travel around the hospital.

University Hospitals Plymouth (UHP) has become the first research site in the world to successfully recruit more than 500 volunteers to ENSEMBLE 2, an international Covid-19 vaccine trial, and remains top of the leader board.

The first results for the Sarscov2 Immunity and Reinfection Evaluation, or SIREN study, currently running at University Hospitals Plymouth (UHP), have revealed that past COVID-19 infection does provide some immunity to the virus for at least five months, but people may still carry and transmit the virus.

University Hospitals Plymouth is currently the top recruiting site across the world for the international Covid-19 vaccine trial which launched on Monday this week.

Six thousand UK volunteers will from today (Monday 16 November) be called upon to join another leading phase three Covid-19 vaccine study, as researchers around the world continue to work to secure a range of vaccines to help tackle coronavirus.

A survey of more than 4,000 UK emergency care doctors has shown that they need more support to recover from work pressures between shifts.

An advanced scanner that could help scientists better understand brain activity and human behaviour has been installed at a new Plymouth research facility.

A team of researchers based in the Westcountry has been awarded nearly £2.5 million from the National Institute for Health Research (NIHR)

A team of researchers based in the Westcountry has been awarded nearly £2.5 million from the National Institute for Health Research (NIHR).

University Hospitals Plymouth (UHP) is currently taking part in a country-wide urgent public health study to understand whether healthcare workers who have antibodies to COVID-19 are protected against future infections of the virus.